Bausch Health

News

Bausch Health hit as Xifaxan successor flunks trials

A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan failed two phase 3 trials.

News

Bausch + Lomb dips on rumour of failing takeover talks

Private equity group Blackstone is reported to be thinking of pulling out of a consortium to buy ophthalmology specialist Bausch + Lomb.

News

Aldeyra spies FDA filing ahead for dry eye drug reproxalap

Aldeyra Therapeutics' dogged persistence with its drug eye disease therapy reproxalap – despite mixed results in a phase 3 trial – may be paying off.

News

Cosmo’s diarrhoea drug approved, threatening Salix’ cash cow

Ireland’s Cosmo Pharma claimed FDA approval for its traveller’s diarrhoea drug Aemcolo, which some analysts say could be a big threat to a rival drug sold by Bausch Health’s Salix unit.

Bausch Health hit as Xifaxan successor flunks trials

Bausch + Lomb dips on rumour of failing takeover talks

Aldeyra spies FDA filing ahead for dry eye drug reproxalap

Cosmo’s diarrhoea drug approved, threatening Salix’ cash cow

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Bausch Health

Editor's Picks